VIRAL CONJUNCTIVITIS DRUGS MARKET ANALYSIS

Market News

Global Viral Conjunctivitis Drugs Market: Key Developments

On June 28, 2023, Bausch + Lomb announced the launch of a social media campaign designed to increase understanding of dry eye disease (DED), one of the most common ocular surface disorders that impacts more than 38 million Americans, and the role of tear evaporation as a leading driver of the disease. The campaign is designed to educate eye care professionals and consumers about DED and foster physician-patient dialogue on this multifactorial disease.

In March 2022, Allergan, an AbbVie company and a pharmaceutical company, announced that LASTACAFT (alcaftadine ophthalmic solution 0.25%) is available without a prescription for the estimated 40% of Americans who live with ocular allergies. As demonstrated in clinical studies, one drop of LASTACAFT works in as little as three minutes to provide relief from itchy, allergic eyes lasting for 16 hours. Following the recent U.S. Food and Drug Administration approval of a complete prescription-to-over-the-counter (OTC) switch, the original patented prescription-strength formulation of LASTACAFT is available online and in retail stores where OTC eye drops are sold.

In October 2021, Bausch + Lomb, and Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS),, announced that the U.S. Food and Drug Administration (FDA) has approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation.

In December 2020, EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced the acquisition of Panoptes Pharma, a privately held clinical-stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need.